M
Marco Montillo
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 215
Citations - 9735
Marco Montillo is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Chronic lymphocytic leukemia & Fludarabine. The author has an hindex of 44, co-authored 208 publications receiving 8118 citations. Previous affiliations of Marco Montillo include Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more
TL;DR: Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL.
Journal ArticleDOI
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
John F. Seymour,Thomas J. Kipps,Barbara Eichhorst,Peter Hillmen,James D’Rozario,Sarit Assouline,Carolyn Owen,John F. Gerecitano,Tadeusz Robak,Javier de la Serna,Ulrich Jaeger,Guillaume Cartron,Marco Montillo,Rod A. Humerickhouse,Elizabeth Punnoose,Yan Li,Michelle Boyer,Kathryn Humphrey,Mehrdad Mobasher,Arnon P. Kater +19 more
TL;DR: Among patients with relapsed or refractory chronic lymphocytic leukemia, venetoclax plus rituximab resulted in significantly higher rates of progression‐free survival than bendamustine plus r ituximac, and the benefit was maintained across all clinical and biologic subgroups.
Journal ArticleDOI
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak,Anna Dmoszynska,Philippe Solal-Celigny,Krzysztof Warzocha,Javier Loscertales,John Catalano,Boris V. Afanasiev,Loree Larratt,Christian H. Geisler,Marco Montillo,Ilya Zyuzgin,Peter Ganly,Caroline Dartigeas,András Rosta,Jörg Maurer,Myriam Mendila,M. Wayne Saville,Nancy Valente,Michael Wenger,Sergey I. Moiseev +19 more
TL;DR: In this article, the authors compared six cycles of rituximab plus fludarabine and cyclophosphamide (R-FC) in patients with previously treated chronic lymphocytic leukemia (CLL).
Journal ArticleDOI
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Wolfgang Knauf,Toshko Lissichkov,Ali Aldaoud,Anna Marina Liberati,Javier Loscertales,Raoul Herbrecht,Gunnar Juliusson,Gerhard Postner,Liana Gercheva,Stefan Goranov,Martin Becker,Hans Joerg Fricke,Françoise Huguet,Ilaria Del Giudice,Peter S. Klein,Lothar Tremmel,Karlheinz Merkle,Marco Montillo +17 more
TL;DR: Bendamustine offers significantly greater efficacy than chlorambucil, and a manageable toxicity profile, when used as first-line therapy in patients with advanced CLL.
Journal ArticleDOI
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Peter Hillmen,Tadeusz Robak,Ann Janssens,K Govind Babu,Janusz Kloczko,Sebastian Grosicki,Michael Doubek,Panagiotis Panagiotidis,Eva Kimby,Anna Schuh,Andrew R. Pettitt,Thomas E. Boyd,Marco Montillo,Ira Gupta,Oliver Wright,Iestyn Dixon,Jodi L Carey,Chai-Ni Chang,Steen Lisby,Astrid McKeown,Fritz Offner +20 more
TL;DR: Addition of ofatumumab to chlorambucil led to clinically important improvements with a manageable side-effect profile in treatment-naive patients with chronic lymphocytic leukaemia who were elderly or had comorbidities.